Treatment with the long-acting monoclonal antibody pemivibart for the prevention of COVID-19 was well tolerated and was associated with no development of symptomatic COVID-19 in the Cohort A oncology subset of the phase 3 CANOPY trial, according to a post hoc analysis.
The results were presented in a poster session at the 2026 ASCO Annual Meeting in Chicago.
The study assessed the safety and outcomes of pemivibart in the oncology subset from the open-label, single-arm, immunocompromised Cohort A of the phase 3 CANOPY trial. The oncology subset included 55 Cohort A participants (18.0% of 306 Cohort A participants).
Among the oncology subset, 40 (73%) had a hematologic malignancy, and 20 (36%) were being actively treated for a solid tumor or hematologic malignancy. Eight participants (14.5%) were receiving immunosuppressants, including 6 (10.9%) receiving corticosteroids.
All Cohort A participants were dosed with 4500 mg of pemivibart (intravenous) on day 1, with a second dose at month 3. Data were analyzed through month 6.
Pemivibart was well tolerated in the CANOPY Cohort A oncology subset. Serious adverse events occurred in 5 (9.1%) participants, with none considered drug-related. No anaphylaxis was reported.
Following pemivibart dosing, sVNA titers in the oncology subset were elevated to levels associated with protection against COVID-19. Through month 6, there was no RT-PCR-confirmed symptomatic COVID-19 in the oncology subset.
The study was funded by Invivyd, Inc.
Leave feedback about this